Role of Serum Regucalcin in Diagnosis of Hepatocellular Carcinoma
试验速览
- 阶段
- 不适用
- 入组人数
- 96
- 试验地点
- 1
- 主要终点
- serum regucalcin in HCC patients
研究概览
简要总结
Although the diagnosis and therapy of HCC have being improved, the poor prognosis still remains. To reduce the mortality and improve the effectiveness of diagnosis and therapy, it is important to detect the protein biomarkers which are associated with HCC tumor progression and may be useful as potential diagnosis or therapeutic targets.
SMP30 (senescence marker protein 30)(serum regucalcin), which we have previously identified from Guangxi HCC cDNA expression library by the SEREX approach, is one of the hepatocellular carcinoma associated antigens [4]
Serum antibody response to SMP30 in various patients using the methods of Western-blot and ELISA and showed that antibody to SMP30 existed mainly in HCC patients (39.8%), especially in the one with alpha-fetoprotein (AFP) negative
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Other
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Newly diagnosed cases of HCC (be based on NCCN guidelines triphasic CT and AFP or liver biopsy)
- •Adult patients
- •Both genders are eligible.
- •Informed consent obtained from subject or subject's legal representative
排除标准
- •Patient with other malignancies.
- •Patients with advanced comorbidities except for renal failure.
- •Prior chemotherapy
结局指标
主要结局
serum regucalcin in HCC patients
时间窗: 1-12-2016 to 1-12-2017
This work aims to assess serum regucalcin antibodies level using ELISA in HCC patients to: * evaluate its potential role as biomarker in diagnosis. * evaluate potential associations of the presence of serum regucalcin antibody with HCC patients' clinico-epidemiological parameters.
次要结局
未报告次要终点
研究者
Ahmed_Elalfy
medical oncology resident
Mansoura University